DK3498692T3 - Isoindolin-sammensætninger og fremgangsmåder til behandling af neurodegenerativ sygdom og makulær degeneration - Google Patents

Isoindolin-sammensætninger og fremgangsmåder til behandling af neurodegenerativ sygdom og makulær degeneration Download PDF

Info

Publication number
DK3498692T3
DK3498692T3 DK19154222.4T DK19154222T DK3498692T3 DK 3498692 T3 DK3498692 T3 DK 3498692T3 DK 19154222 T DK19154222 T DK 19154222T DK 3498692 T3 DK3498692 T3 DK 3498692T3
Authority
DK
Denmark
Prior art keywords
isoindoline
compositions
methods
macular degeneration
neurodegenerative disease
Prior art date
Application number
DK19154222.4T
Other languages
Danish (da)
English (en)
Inventor
Susan M Catalano
Gary C Look
Gilbert Rishton
Original Assignee
Cognition Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognition Therapeutics Inc filed Critical Cognition Therapeutics Inc
Application granted granted Critical
Publication of DK3498692T3 publication Critical patent/DK3498692T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
DK19154222.4T 2014-01-31 2015-01-30 Isoindolin-sammensætninger og fremgangsmåder til behandling af neurodegenerativ sygdom og makulær degeneration DK3498692T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461934528P 2014-01-31 2014-01-31
EP15743281.6A EP3099296B1 (en) 2014-01-31 2015-01-30 Isoindoline derivative, compositions and methods for treating neurodegenerative disease

Publications (1)

Publication Number Publication Date
DK3498692T3 true DK3498692T3 (da) 2022-05-16

Family

ID=53757753

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19154222.4T DK3498692T3 (da) 2014-01-31 2015-01-30 Isoindolin-sammensætninger og fremgangsmåder til behandling af neurodegenerativ sygdom og makulær degeneration
DK15743281.6T DK3099296T3 (en) 2014-01-31 2015-01-30 ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15743281.6T DK3099296T3 (en) 2014-01-31 2015-01-30 ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE

Country Status (15)

Country Link
US (5) US9796672B2 (enExample)
EP (3) EP3498692B1 (enExample)
JP (1) JP6517827B2 (enExample)
KR (1) KR102331422B1 (enExample)
CN (1) CN106163516B (enExample)
AU (1) AU2015210852B2 (enExample)
BR (1) BR112016017808B1 (enExample)
CA (1) CA2938212C (enExample)
DK (2) DK3498692T3 (enExample)
ES (2) ES2721001T3 (enExample)
IL (1) IL247003B (enExample)
MX (1) MX368755B (enExample)
NZ (1) NZ722599A (enExample)
RU (1) RU2692258C2 (enExample)
WO (1) WO2015116923A1 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2794565B1 (en) 2011-12-21 2017-07-26 Novira Therapeutics Inc. Hepatitis b antiviral agents
CA2881057C (en) 2012-08-28 2020-10-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
JP6466348B2 (ja) 2013-02-28 2019-02-06 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
TW202126620A (zh) 2013-05-17 2021-07-16 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
WO2015116923A1 (en) * 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
JP6553059B2 (ja) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Ｈｂｖ感染の治療のための併用療法
PL3102572T3 (pl) 2014-02-06 2019-04-30 Janssen Sciences Ireland Uc Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
AR106192A1 (es) 2015-09-29 2017-12-20 Novira Therapeutics Inc Formas cristalinas de un agente antiviral contra la hepatitis b
US11046670B2 (en) 2015-10-19 2021-06-29 Board Of Regents, The University Of Texas System Piperazinyl norbenzomorphan compounds and methods for using the same
WO2017181141A2 (en) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
AU2017257153A1 (en) 2016-04-29 2018-11-22 Board Of Regents, The University Of Texas System Sigma receptor binders
CN107162944B (zh) * 2017-04-27 2019-02-26 湖南化工研究院有限公司 2,3-二甲基苯甲硫醚的制备方法
ES3063712T3 (en) * 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
US20200338045A1 (en) * 2017-11-01 2020-10-29 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
SG11202007097QA (en) 2018-03-14 2020-08-28 Janssen Sciences Ireland Unlimited Co Capsid assembly modulator dosing regimen
JP6567153B1 (ja) * 2018-09-28 2019-08-28 学校法人東北工業大学 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム
WO2020092693A1 (en) * 2018-10-31 2020-05-07 Polycore Therapeutics Llc Method for synthesizing d3 dopamine receptor agonists
AU2020223865A1 (en) 2019-02-22 2021-07-15 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
CN109734638A (zh) * 2019-03-08 2019-05-10 新昌县大船畈生物科技有限公司 一种食用香精香料的制备方法
CN109734639B (zh) * 2019-03-08 2020-10-09 漯河市卫龙生物技术有限公司 一种食用香精香料的制备方法
BR112021021454A2 (pt) 2019-05-06 2021-12-21 Janssen Sciences Ireland Unlimited Co Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv
US12352719B2 (en) 2019-09-20 2025-07-08 KYCERA AVX Components Corporation Somatic cell-based electrical biosensor
CN112694427B (zh) * 2019-10-23 2022-11-18 江西天宇化工有限公司 一种制备2,3-二甲基苯甲硫醚的方法
KR20220142477A (ko) * 2020-02-13 2022-10-21 카그니션 테라퓨틱스, 인코퍼레이티드 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법
IL298323B2 (en) 2020-05-20 2023-10-01 Univ Illinois A method for treating lysosomal storage disease using histatin peptides
CN116867488A (zh) * 2020-12-11 2023-10-10 考格尼申治疗股份有限公司 用于治疗干性老年性黄斑变性（amd）的组合物
CA3212092A1 (en) * 2021-03-19 2022-09-22 Cognition Therapeutics, Inc. Compositions and methods for treating neurologic diseases
WO2024020059A1 (en) * 2022-07-18 2024-01-25 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
US20260216139A1 (en) * 2022-12-14 2026-07-30 Fred Hutchinson Cancer Center Method for treating neurological diseases through glial pruning regulation
WO2024196799A2 (en) * 2023-03-17 2024-09-26 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
CN117945980A (zh) * 2024-01-24 2024-04-30 上海健康医学院 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用
WO2026064542A1 (en) 2024-09-18 2026-03-26 Cognition Therapeutics, Inc. 2-(tert-butoxy)-4-(3-methyl-3-(5-(methylsulfonyl)isoindolin-2-yl)butyl)phenol fumarate salts in solid forms
WO2026064543A1 (en) 2024-09-18 2026-03-26 Cognition Therapeutics, Inc. Process for preparing 2-(tert-butoxy)-4-(3-methyl-3-(5-methylsulfonyl)isoindolin-2-yl)butyl)phenol
WO2026119142A1 (zh) * 2024-12-03 2026-06-11 浙江径科医药有限公司 一种氘代异吲哚啉化合物及其应用

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA732136B (en) 1972-04-12 1974-03-27 Lilly Co Eli Dopamine derivatives
DE2753278A1 (de) 1977-11-30 1979-05-31 Basf Ag Aralkylpiperidinone
US4321386A (en) 1981-01-28 1982-03-23 Mead Johnson & Company Quaternary piperidinium halides
DE3222152A1 (de) 1982-06-12 1983-12-15 Bayer Ag, 5090 Leverkusen Substituierte maleinsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
FI81713C (fi) 1983-01-31 1990-12-10 Lilly Co Eli Foerfarande och djurfoderpremix foer befraemjande av tillvaexten, foerbaettring av utnyttjandegraden av foder eller minskning av fetthalten i koett hos ett husdjur.
JPS62283922A (ja) 1986-05-30 1987-12-09 Tsumura Juntendo Inc 血小板凝集抑制剤
US4697024A (en) 1986-11-24 1987-09-29 Merrell Dow Pharmaceuticals Inc. Medroxalol intermediates
US4958029A (en) * 1987-01-13 1990-09-18 Banyu Pharmaceutical Co., Ltd. Process for the production of isoindoline derivatives, novel intermediates and process for their production
JPH01180822A (ja) 1988-01-12 1989-07-18 Dainippon Pharmaceut Co Ltd 抗遅延型アレルギー剤
JPH01305085A (ja) 1988-05-31 1989-12-08 Yamanouchi Pharmaceut Co Ltd ピリジルチアゾリジンカルボン酸アミド誘導体
JPH02215789A (ja) 1989-02-15 1990-08-28 Yamanouchi Pharmaceut Co Ltd チアゾロ［３，４―ａ］ピラジン誘導体
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
DE4000610A1 (de) 1990-01-11 1991-07-18 Knoll Ag Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen
JP2818958B2 (ja) 1990-02-23 1998-10-30 塩野義製薬株式会社 ４―（４―アルコキシフェニル）―２―ブチルアミン誘導体およびその製造法
JPH045266A (ja) 1990-04-24 1992-01-09 Toyo Pharma- Kk ドパミン誘導体の製造方法
DE4142366A1 (de) 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU702629B2 (en) 1991-08-23 1999-02-25 Nps Pharmaceuticals, Inc. Calcium receptor-active arylalkyl amines
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
JPH06321781A (ja) 1993-05-13 1994-11-22 Yamanouchi Pharmaceut Co Ltd 血小板活性化因子拮抗剤
EP1275635A1 (en) 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
JPH0915744A (ja) 1995-06-29 1997-01-17 Fuji Photo Film Co Ltd 磁気ヘッドの検査方法及びフィルムキャリア
JP3522930B2 (ja) 1995-12-06 2004-04-26 花王株式会社 抗菌剤及びこれを含有する口腔用組成物
WO1997030038A1 (en) 1996-02-15 1997-08-21 Mitsubishi Chemical Corporation Diarylsultam derivatives
US6235731B1 (en) 1996-04-24 2001-05-22 Takeda Chemical Industries, Ltd. Fused imidazopyridine derivatives as antihyperlipidemic agents
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6518315B1 (en) 1997-10-21 2003-02-11 The University Of Sydney Medicinal uses of phenylaikanols and derivatives
CO4980891A1 (es) 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
CO5011072A1 (es) 1997-12-05 2001-02-28 Lilly Co Eli Etanolaminas pirazinil substituidas como agfonistas de los receptores
IL138686A0 (en) 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
AU2300001A (en) 1999-10-22 2001-05-08 Board Of Trustees Of The University Of Illinois, The Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
DE10027151A1 (de) 2000-05-31 2001-12-06 Bayer Ag Herbizide Mittel auf Basis von substituierten Carbonsäureamiden
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
WO2002070647A2 (en) 2001-03-05 2002-09-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses
JP4312402B2 (ja) 2001-07-31 2009-08-12 有限会社大長企画 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤
WO2003016274A2 (en) 2001-08-21 2003-02-27 Sepracor, Inc. 2-substituted piperidines that are ligands for monoamine receptors and transporters
US6991814B2 (en) 2001-12-13 2006-01-31 Council Of Scientific And Industrial Research Herbal medicaments for the treatment of neurocerebrovascular disorders
UA82057C2 (en) 2001-12-14 2008-03-11 Каунсил Оф Сайентифик Энд Индастриал Рисёрч COMPOSITION basED on AR-D-turmeron and α- anD β-turmeron FOR TREATING NEUROCEREBROVASCULAR DISORDERS
JP2004002517A (ja) 2002-05-31 2004-01-08 Dae Sil Kim 生姜成分を含む石鹸の組成物及びその製造方法
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DE10320560A1 (de) 2003-05-07 2004-01-29 Brosig, Stefan, Dr. Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit
US7829562B2 (en) 2003-06-12 2010-11-09 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
EP1635805A4 (en) 2003-06-12 2007-08-08 Ms Science Corp SIGMA RECEPTOR LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RE-ESTABLISHMENT
SK50802006A3 (sk) 2004-03-12 2007-03-01 Egis Gy�gyszergy�r Nyrt. Kombinovaná farmaceutická kompozícia na inhibíciupoklesu kognitívnych funkcií
AU2005247251A1 (en) 2004-05-31 2005-12-08 Kaneka Corporation Agent for preventing/amelioratig life style-relaetd diseases containing turmeric essential oil component
ES2415665T3 (es) 2004-06-21 2013-07-26 Proteome Sciences Plc Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US20080153917A1 (en) 2004-09-10 2008-06-26 Ucb Pharma, S.A. Sigma Receptor Ligands
WO2006047254A1 (en) 2004-10-22 2006-05-04 Regents Of The University Of Minnesota Assemblies of oligomeric amyloid beta protein and uses thereof
US20060153772A1 (en) 2004-12-15 2006-07-13 Wyeth Contextual fear conditioning for predicting immunotherapeutic efficacy
KR20080021585A (ko) 2005-03-05 2008-03-07 애보트 게엠베하 운트 콤파니 카게 스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법
EP1896005A4 (en) 2005-06-15 2009-11-11 Darrick S H L Kim SYNERGISTIC PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF BETA AMYLOID PROTEIN-INDUCED DISEASES WITH SALBEI AND ROSMARIN COMPOUNDS
TW200726774A (en) 2005-06-30 2007-07-16 Merck & Co Inc Composition and method for producing stable amyloid beta oligomers
US20070021413A1 (en) 2005-07-20 2007-01-25 Peter Herold Diamino alcohols as therapeutic compounds
ITRM20060007A1 (it) 2006-01-05 2007-07-06 Univ Bari Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici
US20070218491A1 (en) 2006-02-08 2007-09-20 Oligomerix, Inc. Oligomerization of amyloid proteins
CA2644093A1 (en) 2006-03-17 2007-09-27 Herbalscience Singapore Pte. Ltd. Extracts and methods comprising curcuma species
US20100029654A1 (en) 2006-03-23 2010-02-04 Mount Sinai School Of Medicine Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
WO2007126473A2 (en) 2006-04-10 2007-11-08 Oligomerix, Inc. Oligomerization of amyloid proteins
US8357781B2 (en) 2006-06-01 2013-01-22 Janssen Alzheimer Immunotherapy Neuroactive fragments of APP
US7561775B2 (en) 2006-08-22 2009-07-14 Senko Advanced Components, Inc. Fiber optic protective shutter
EP2066692B1 (en) 2006-09-08 2012-01-11 VIB, vzw Means and methods for the production of amyloid oligomers
US7723377B2 (en) 2006-09-29 2010-05-25 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
US20080131233A1 (en) 2006-10-17 2008-06-05 Yao Chun I Plate-shaped fastener device
US20100028333A1 (en) 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
US20080171757A1 (en) 2007-01-11 2008-07-17 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Serivces Methods to identify inhibitors of cell sickling
EP2152744A4 (en) 2007-04-26 2012-02-15 Univ Yale PRION PROTEIN AS RECEPTOR FOR AMYLOID-BETA OLIGOMERS
US7968524B2 (en) 2007-05-15 2011-06-28 Helicon Therapeutics, Inc. Methods of enhancing long term memory formation by inhibition of Gpr12
CN101121670A (zh) 2007-09-11 2008-02-13 上海紫源制药有限公司 一种3,4-二甲氧基-N-[3-(4-甲氧基苯基)-1-甲基-正丙基]-β-苯乙胺盐酸盐的制备方法
WO2009048631A1 (en) 2007-10-11 2009-04-16 University Of Tennessee Research Foundation PREPARATION OF PURIFIED COVALENTYLY CROSS-LINKED A β OLIGOMERS AND USES THEREOF
SI2206707T1 (sl) 2007-10-24 2014-11-28 Astellas Pharma Inc. Azolkarboksamidna spojina ali njena sol
US8168800B2 (en) 2007-11-02 2012-05-01 The Regents Of The University Of California Aβ-binding small molecules
US20110092554A1 (en) 2007-11-19 2011-04-21 Richard Chesworth 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
EP2303920A4 (en) 2008-07-25 2011-11-09 Abbott Lab SS-AMYLOID PEPTIDE ANALOGUES, OLIGOMERS THEREOF, PREPARATION METHODS AND COMPOSITIONS COMPRISING THE SAME OR OLIGOMERIC ANALOGUES, AND USES THEREOF
KR101515822B1 (ko) 2008-11-29 2015-04-29 더 타일랜드 리서치 펀드 바이러스와 타겟 세포의 상호작용 저해
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
JP5730280B2 (ja) 2009-03-16 2015-06-03 パング バイオファーマ リミテッド 非カノニカル生物学的活性を有するヒスチジル−ｔＲＮＡシンテターゼスプライスバリアントを含む組成物および方法
US7972164B2 (en) 2009-03-24 2011-07-05 Tyco Electronics Corporation Connector assembly with a latch
WO2010118055A1 (en) * 2009-04-09 2010-10-14 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
US9493834B2 (en) 2009-07-29 2016-11-15 Pharnext Method for detecting a panel of biomarkers
RU2012107457A (ru) 2009-07-31 2013-09-10 Когнишн Терапьютикс, Инк. Ингибиторы ухудшения когнитивных способностей
US20150160228A1 (en) 2010-02-05 2015-06-11 Susan Catalano Compositions and method for determining the efficacy of amyloidosis treatments
US20130071330A1 (en) 2010-02-26 2013-03-21 Susan Catalano Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
WO2012027548A1 (en) 2010-08-25 2012-03-01 The Feinstein Institute For Medical Research Compounds and methods for prevention and treatment of alzheimer's and other diseases
US20170049723A1 (en) 2011-02-02 2017-02-23 Cognition Therapeutics, Inc. Isolated compounds from turmeric oil and methods of use
SG192596A1 (en) 2011-02-02 2013-09-30 Cognition Therapeutics Inc Isolated compounds from turmeric oil and methods of use
WO2013029057A2 (en) * 2011-08-25 2013-02-28 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
US20140378460A1 (en) 2011-08-25 2014-12-25 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
AT511906B1 (de) 2011-08-30 2016-05-15 Blum Gmbh Julius Schublade
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
WO2015116923A1 (en) * 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
ES3063712T3 (en) 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
US20200338045A1 (en) * 2017-11-01 2020-10-29 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
CN110283082A (zh) 2019-07-15 2019-09-27 泰州职业技术学院 一种3-苯基丙胺的制备方法
KR20220142477A (ko) 2020-02-13 2022-10-21 카그니션 테라퓨틱스, 인코퍼레이티드 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법
CN116867488A (zh) 2020-12-11 2023-10-10 考格尼申治疗股份有限公司 用于治疗干性老年性黄斑变性（amd）的组合物

Also Published As

Publication number Publication date
US11691947B2 (en) 2023-07-04
EP4023294A1 (en) 2022-07-06
HK1225651A1 (zh) 2017-09-15
US20180086703A1 (en) 2018-03-29
IL247003A0 (en) 2016-09-29
EP3498692B1 (en) 2022-03-16
US20190210966A1 (en) 2019-07-11
MX368755B (es) 2019-10-15
AU2015210852B2 (en) 2019-01-24
US10207991B2 (en) 2019-02-19
EP3099296B1 (en) 2019-01-30
CN106163516A (zh) 2016-11-23
JP2017507122A (ja) 2017-03-16
BR112016017808A2 (pt) 2017-08-08
BR112016017808B1 (pt) 2022-07-12
ES2915833T3 (es) 2022-06-27
US20210009517A1 (en) 2021-01-14
MX2016009845A (es) 2017-02-22
CA2938212C (en) 2023-03-14
US10611728B2 (en) 2020-04-07
RU2016134677A3 (enExample) 2018-09-14
IL247003B (en) 2019-09-26
ES2721001T3 (es) 2019-07-26
US20170144970A1 (en) 2017-05-25
CN106163516B (zh) 2019-05-28
CA2938212A1 (en) 2015-08-06
EP3099296A1 (en) 2016-12-07
KR20160108564A (ko) 2016-09-19
RU2692258C2 (ru) 2019-06-24
AU2015210852A1 (en) 2016-08-11
RU2016134677A (ru) 2018-03-01
JP6517827B2 (ja) 2019-05-22
EP3498692A1 (en) 2019-06-19
WO2015116923A1 (en) 2015-08-06
NZ722599A (en) 2022-05-27
BR112016017808A8 (pt) 2020-06-30
US9796672B2 (en) 2017-10-24
US20240150288A1 (en) 2024-05-09
US12466795B2 (en) 2025-11-11
DK3099296T3 (en) 2019-04-15
EP3099296A4 (en) 2017-07-19
KR102331422B1 (ko) 2021-11-25

Similar Documents

Publication Publication Date Title
IL247003A0 (en) Isoindoline compounds and methods for the treatment of neurodegenerative diseases
DK3206493T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3386518T3 (da) Metoder og sammensætninger til behandling af en serpinc1-associeret forstyrrelse
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
SI3594238T1 (sl) Sestavki protiteles za zdravljenje tumorja
DK3206497T3 (da) Sammensætninger og fremgangsmåder til behandling af meibomsk kirtel-dysfunktion
DK3137605T3 (da) Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
DK3316909T3 (da) Anti-ntb-a-antistoffer og relaterede sammensætninger og fremgangsmåder
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3245225T3 (da) Sammensætninger og fremgangsmåder til behandling og detektering af cancere
DK3134130T3 (da) Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3324932T3 (da) Sammensætninger og fremgangsmåder for nanopartikel lyofile former
DK2924093T3 (da) Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3102232T3 (da) Fremgangsmåder og sammensætninger til behandling af abnorm cellevækst
DK3164716T3 (da) Fremgangsmåde til diagnosticering af neurodegenerative sygdomme
DK3148517T3 (da) Sammensætninger og fremgangsmåder til fremme af knogledannelse
ME03783B (me) Polimeri koji vezuju protone za oralnu primjenu
ZA201606199B (en) Compositions and methods for treating diabetes and liver diseases
IL247116B (en) Compositions and methods for treating and preventing macular degeneration
DK3848028T5 (da) Fremgangsmåder til behandling af øjenlidelser
DK3250550T3 (da) Sammensætninger og fremgangsmåder til virussensibilisering